NATICK, Mass., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. announces oral presentations at the 2013 ACR Annual Meeting on the use of its oral SINE XPO1 antagonists in preclinical models of Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). Preclinical evidence suggests that XPO1 antagonists lead to the nuclear accumulation of I-kB, the inhibitor of the pro-inflammatory protein nuclear factor kB (NF-kB). This leads to inhibition of NF-kB activity, which could reduce inflammation.
Teresa Owen from Jennifer Anolik Laboratory, Department of Medicine at the University of Rochester (New York), is presenting "Novel Selective Inhibitors of Nuclear Export (SINE) Decrease Type I Interferon Activation and Deplete Autoreactive Plasma Cells in the Kidney in Murine Lupus" at the ACR Annual Meeting in San Diego on October 30, 2013 at Hilton – Indigo C in the Systemic Lupus Erythematosus – Animal Models session (Abstract #2890).
Mwanasha Hamuza of Karyopharm will present "Selective Inhibitors of Nuclear Export (SINE) for Treatment of Rheumatoid Arthritis" at the ACR Annual Meeting in San Diego, CA on October 28, 2013 at 32B (San Diego Convention Center) in the Rheumatoid Arthritis – Animal Models I session (Abstract #1727).
Dr. Sharon Shacham, Karyopharm's founder, Chief Scientific Officer, and President of Research and Development commented, "These presentations reflect our research into the use of our oral SINE compounds in preclinical models of autoimmune and inflammatory diseases which we are currently studying, which complement our ongoing Phase 1 clinical trials of our first-in-class SINE XPO1 antagonist Selinexor (oral KPT-330) for the treatment of various advanced cancers."
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company founded by Dr. Sharon Shacham in December 2008. Karyopharm, led by Dr. Shacham and co-founded by Dr. Michael Kauffman, is focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitors of Nuclear Export (SINE) compounds function by preventing the export of tumor suppressor proteins from the nucleus of a cell, thereby leading to their accumulation in the nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. The compounds are also being investigated in preclinical models of autoimmune and inflammatory diseases, viral infections, and wound healing. Karyopharm is located in Natick, Massachusetts.
Source: Karyopharm Therapeutics